1-2 of 2
Pearl van Heteren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Free
Peter Borchmann, Tom Van Meerten, Pierre Bories, Peter Dreger, Laszlo Gopsca, Pim Mutsaers, Matthias Edinger, Arpad Illes, Bastian von Tresckow, Peter Neumeister, Normann Steiner, Ulrich Jaeger, Ana Triguero Moreno, Laimonas Griškevičius, Gloria Iacoboni, François Lemonnier, Jaap Van Doesum, Nirav Shah, Rimas Orentas, Stefan Miltenyi, Toon Overstijns, Iris Bürger, Gregor Zadoyan, Corinne Brillant, Pearl van Heteren, Silke Holtkamp, Peter Vandenberghe
Journal: Blood
Blood (2025) 146 (Supplement 1): 669.
https://doi.org/10.1182/blood-2025-669
Published: 2025
Journal Articles

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Free
Bertram Glass, Bettina Altmann, Matthias Stelljes, Georg Lenz, Julia Marx, Justin Hasenkamp, Frank P. Kroschinsky, Anna Ossami Saidy, Peter Dreger, Lutz Peter Hermann Mueller, Inken Hilgendorf, Gerald Illerhaus, Guido Kobbe, Roland Schroers, Katrin Linke, Carsta Koehler, Norbert Schmitz, Marita Ziepert, Pearl van Heteren
Journal: Blood
Blood (2023) 142 (Supplement 1): 231.
https://doi.org/10.1182/blood-2023-173179
Published: 2023